The FDA Psychopharmacologic Drug Advisory Committee and Drug Safety and Risk Management Advisory Committee jointly voted on the benefit-risk profile of esketamine nasal spray for the treatment of adults...
The FDA Psychopharmacologic Drug Advisory Committee and Drug Safety and Risk Management Advisory Committee jointly voted on the benefit-risk profile of esketamine nasal spray for the treatment of adults...
The FDA Psychopharmacologic Drug Advisory Committee and Drug Safety and Risk Management Advisory Committee jointly voted on the benefit-risk profile of esketamine nasal spray for the treatment of adults...
The FDA has approved the first therapy specifically indicated (in combination with plasma exchange and immunosuppressive therapy) for the treatment of adults with acquired thrombotic thrombocytopenic...
The FDA has approved the first therapy specifically indicated (in combination with plasma exchange and immunosuppressive therapy) for the treatment of adults with acquired thrombotic thrombocytopenic...
The FDA has approved the first therapy specifically indicated (in combination with plasma exchange and immunosuppressive therapy) for the treatment of adults with acquired thrombotic thrombocytopenic...
The FDA has approved the first generic of a common treatment option for asthma in patients and for maintenance treatment of airflow obstruction and reduction of exacerbations in patients with chronic...
An advisory panel to the FDA has recommended the approval of a new treatment option for use in postmenopausal women with osteoporosis and high fracture risk.
An advisory panel to the FDA has recommended the approval of a new treatment option for use in postmenopausal women with osteoporosis and high fracture risk.
An advisory panel to the FDA has recommended the approval of a new treatment option for use in postmenopausal women with osteoporosis and high fracture risk.
